{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:22:27Z","timestamp":1776201747416,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Identifying immunologic predictors of clinical responses remains an unmet need in the era of biologic therapy for psoriasis. Super responders (SRs), defined as patients achieving complete skin clearance within weeks of treatment initiation, represent an emerging clinical endotype; however, their immunological profiles remain insufficiently characterized. We conducted a prospective observational study to characterize serum cytokine profiles associated with SR status in biologic-na\u00efve patients with moderate-to-severe plaque psoriasis treated with secukinumab, an IL-17A inhibitor. Twenty-eight patients were enrolled and stratified at week 12 into SR (PASI = 0; n = 9) and non-super responder (NSR; PASI &gt; 0; n = 19) groups. Serum concentrations of 19 cytokines were analyzed at baseline and after 12 weeks of treatment. SRs displayed a distinct immunological signature characterized by significantly higher IL-13 and lower IL-18 baseline levels compared to NSRs (p = 0.002 and p = 0.007, respectively), alongside reduced baseline monocyte counts. L1-regularized logistic regression confirmed IL-13 and IL-18 as strong independent predictors of SR status (AUC = 0.91). Moreover, the IL-18\/IL-13 ratio emerged as a highly discriminative biomarker (p = 0.00001, AUC = 0.86). Notably, SRs exhibited a more pronounced decline in IL-18 and IL-23 during treatment. Our findings provide novel insights into the immunopathogenesis of super response and suggest that an immunological milieu favoring Th2 polarization may promote superior outcomes with IL-17A blockade. Incorporating IL-13, IL-18, and their ratio into clinical algorithms may facilitate precision-guided biologic therapy in psoriasis.<\/jats:p>","DOI":"10.3390\/ijms26136432","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T03:47:26Z","timestamp":1751600846000},"page":"6432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum IL-18\/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis"],"prefix":"10.3390","volume":"26","author":[{"given":"Dominika","family":"Ziolkowska-Banasik","sequence":"first","affiliation":[{"name":"Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7241-9685","authenticated-orcid":false,"given":"Maciej","family":"Pastuszczak","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Zawadzinska-Halat","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Hadas","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-2263","authenticated-orcid":false,"given":"Andrzej","family":"Bozek","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar to and distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wu, L.-T.-Y., Qiao, Z.-H., Tian, J.-B., Lin, J.-L., Hou, S.-C., and Liu, X.-M. (2023). The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity. Skin Res. Technol., 29.","DOI":"10.1111\/srt.13405"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Solberg, S.M., de Boer, J., Langholz, E., Dyrhol-Riise, A.M., and Skov, L. (2018). Serum cytokine measurements and biological therapy of psoriasis\u2014Prospects for individualized therapy. Scand. J. Immunol., 87.","DOI":"10.1111\/sji.12725"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., Damiani, G., Dapavo, P., and Dini, V. (2024). Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: A retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis). Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1341708"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/bjd\/ljad280","article-title":"How to define a \u2018super-responder\u2019 to biologics in psoriasis studies","volume":"189","author":"Thomas","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/bjd\/ljad446","article-title":"Characteristics of \u2018super responders\u2019 and \u2018super non-responders\u2019 to first biologic monotherapy for psoriasis: A nested case-control study","volume":"190","author":"Mason","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: A nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Marcelli, L., Belcastro, A., Talamonti, M., Galluzzo, M., Giunta, A., Bavetta, M., Perino, F., Cortese, C., Bianchi, L., and Chimenti, S. (2024). Characterization of super-responder profile in chronic plaque psoriatic patients under guselkumab treatment: A long-term real-life experience. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175175"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2331782","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: A real-life cohort study on the effectiveness and drug survival over one year","volume":"35","author":"Liu","year":"2024","journal-title":"J. Dermatolog. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/PTT.S514249","article-title":"Real-world experience of bimekizumab in a cohort of 109 patients over 48 weeks and identification of predictive factors for an early super response and risk of adverse events","volume":"15","author":"Fratton","year":"2025","journal-title":"Psoriasis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s13555-025-01394-2","article-title":"Predictive factors for super responder status and long-term effectiveness of guselkumab in psoriasis: A multicenter retrospective study","volume":"15","author":"Mortato","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hsieh, C.L., Yu, S.J., Lai, K.L., Chao, W.T., and Yen, C.Y. (2024). IFN-gamma, IL-17A, IL-4, and IL-13: Potential biomarkers for prediction of the effectiveness of biologics in psoriasis patients. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051115"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ruscitti, P., Esposito, M., Di Cola, I., Pellegrini, C., De Berardinis, A., Mastrangelo, M., Gianneramo, C., Barile, A., Fargnoli, M.C., and Cipriani, P. (2023). Cytokine profile characterization of na\u00efve patients with psoriasis and psoriatic arthritis: Implications for a pathogenic disease continuum. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1229516"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/jid.2011.458","article-title":"A single intradermal injection of IFN-\u03b3 induces an inflammatory state in both non-lesional psoriatic and healthy skin","volume":"132","author":"Pierson","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rusi\u00f1ol, L., and Puig, L.A. (2024). Narrative Review of the IL-18 and IL-37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202406.1196.v1"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yasuda, K., Nakanishi, K., and Tsutsui, H. (2019). Interleukin-18 in health and disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030649"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/00015550310016508","article-title":"Serum levels of IL-18 in patients with psoriasis","volume":"83","author":"Pietrzak","year":"2003","journal-title":"Acta Derm. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Orzan, O.A., Tutunaru, C.V., and Iano\u0219i, S.L. (2025). Understanding the intricate pathophysiology of psoriasis and related skin disorders. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020749"},{"key":"ref_23","first-page":"102","article-title":"Expression of Th1 and Th2 cytokine and associated transcription factors in peripheral blood mononuclear cells and correlation with disease severity","volume":"6","author":"Yousefzadeh","year":"2017","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1523-1747.2002.19509.x","article-title":"Interleukin-13 Receptor in Psoriatic Keratinocytes: Overexpression of the mRNA and Underexpression of the Protein","volume":"119","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.36849\/JDD.7525","article-title":"Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis","volume":"23","author":"Hadas","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"ten Bergen, L.L., Petrovic, A., Aarebrot, A.K., and Appel, S. (2020). The TNF\/IL-23\/IL-17 Axis\u2014Head-to-Head Trials Comparing Different Biologics in Psoriasis Treatment. Scand. J. Immunol., 92.","DOI":"10.1111\/sji.12946"},{"key":"ref_27","first-page":"1044","article-title":"Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-\u03b1","volume":"45","author":"Yamamoto","year":"2018","journal-title":"J. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:04:13Z","timestamp":1760033053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":27,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136432"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136432","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}